M&A Acquirer Playbook

10x Genomics, Inc. acquisition history.

Every deal, price, and strategic rationale.

Company 10x Genomics, Inc.
SEC CIK 0001770787
Tracked filings EDGAR · 8-K
Total deals tracked
5
Disclosed 8-K acquisitions, 2020 — present.
Aggregate disclosed value
$0.46B
approximately $0.46 billion across the 3 transactions with a disclosed price (of 5 total); the two earliest deals (Epinomics and Spatial Transcriptomics) were undisclosed.
Active acquisition years
2018 · 2020
Single major deal per active year.
Primary sectors
Single-cell and spatial genomics technology
each deal acquired foundational IP for a product platform: Epinomics (ATAC-seq for Chromium), Spatial Transcriptomics (Visium), ReadCoor and CartaNA (In Situ / Xenium), and Tetramer Shop (immunology reagents).
Verified 3 deals on this page · sourced from SEC filings
All cross-references covered.
Timeline

3 deals, $0.46B deployed.

Plotted by close date where disclosed, otherwise announcement. Click any marker to jump to the deal entry.

$41.8M Aug 2020 CartaNA AB $407.4M Oct 2020 ReadCoor $8.5M Jan 2021 Tetramer Shop ApS
The playbook

The rationale that repeats.

Three patterns show up across 10x Genomics's deal book — what the team buys, how it pays, and how it integrates. The patterns are the throughline; the individual deals below are the evidence.

01
Acquisition criteria

Acquire the foundational technology, then turn it into a product platform.

Every 10x Genomics acquisition brought in foundational IP that became the basis of a named product line: Epinomics' ATAC-seq fed the Chromium Single Cell ATAC Solution, Spatial Transcriptomics became Visium, and ReadCoor plus CartaNA together formed the foundation of the Xenium In Situ platform. The deals were technology and IP buys, not revenue or distribution plays.

CartaNA ABReadCoorTetramer Shop ApS
02
Capital deployment

Buy out competing approaches to lock up an emerging field.

In the In Situ space, 10x acquired both ReadCoor (a Harvard spinout from George Church's lab) and CartaNA (out of Mats Nilsson's lab at Stockholm University) within the same announcement, combining more than 110 In Situ patents and applications. Management framed both deals as the result of a comprehensive assessment of In Situ efforts worldwide — consolidating the strongest teams and IP rather than competing against them.

CartaNA ABReadCoorTetramer Shop ApS
03
Integration approach

A strong Scandinavian R&D footprint.

Three of the five targets were Northern European — Spatial Transcriptomics and CartaNA in Stockholm and Tetramer Shop in Copenhagen — and the acquired teams were folded into 10x's Swedish research center. The pattern reflects 10x sourcing deep academic expertise in spatial and in situ biology directly from the European labs that pioneered those methods.

CartaNA ABReadCoorTetramer Shop ApS
Deal book · 3 acquisitions

The full deal book.

3 acquisitions. Click any row to see the deal value, financing structure, target revenue, executive commentary, and the original SEC filing — the evidence behind the patterns above.

More acquirer playbooks

NIKE, Inc.CMS ENERGY CORPKIRBY CORPPLEXUS CORPBIO-RAD LABORATORIES, INC.KEYCORP /NEW/
VectorShift for deal teams

Put VectorShift to work
on every deal.

VectorShift reads the documents your team actually works on — CIMs, management decks, filings, expert calls, portfolio reports — and returns structured, sourced analysis in minutes, not weeks.

Request a demo